Oxidative Modifications of α‐Synuclein

Abstract: Hallmark lesions of neurodegenerative synucleinopathies contain α‐synuclein (α‐syn) that is modified by nitration of tyrosine residues and possibly by dityrosine cross‐linking to generated stable oligomers. Data gathered from in vitro experiments and from model systems of cells transfected with wild‐type and mutant α‐syn revealed that conditions resulting in α‐syn nitration also induce formation of α‐syn inclusions with similar biochemical characteristics to protein extracted from human lesions. The detection of tyrosine‐nitrated α‐syn signifies the formation of reactive nitrogen species capable of both radical and electrophilic attack on aromatic residues as well as nucleophilic additions and oxidations. The cellular sources and biochemical reactivity of reactive nitrogen species in the central nervous system remain largely unknown, but kinetically fast reactions of nitric oxide with superoxide to form peroxynitrite as well as enzymatic one‐electron oxidation of nitrite are two important sources of reactive nitrogen species. Based on these findings a model is proposed where the process of fibrilization can be differentially affected by oxidants and nitrating species. Posttranslational modifications of α‐syn by reactive nitrogen species inhibits fibril formation and results in urea‐ and SDS‐ insoluble, protease‐resistant α‐syn aggregates that maybe responsible for cellular toxicity.

[1]  J. Trojanowski,et al.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.

[2]  W. Markesbery,et al.  Electrochemical Analysis of Protein Nitrotyrosine and Dityrosine in the Alzheimer Brain Indicates Region-Specific Accumulation , 1998, The Journal of Neuroscience.

[3]  Joseph Loscalzo,et al.  A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds , 1993, Nature.

[4]  E. Masliah,et al.  Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.

[5]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[6]  M. Moskowitz,et al.  Mechanisms of Reduced Striatal NMDA Excitotoxicity in Type I Nitric Oxide Synthase Knock-Out Mice , 1997, The Journal of Neuroscience.

[7]  J. Payton,et al.  Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. , 2001, Brain research. Molecular brain research.

[8]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[9]  J. Langston,et al.  Novel α-Synuclein-Immunoreactive Proteins in Brain Samples from the Contursi Kindred, Parkinson's, and Alzheimer's Disease , 1998, Experimental Neurology.

[10]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[11]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[12]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[13]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[14]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[15]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[16]  O. Bagasra,et al.  Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[18]  J. Schulz,et al.  Striatal Malonate Lesions Are Attenuated in Neuronal Nitric Oxide Synthase Knockout Mice , 1996, Journal of neurochemistry.

[19]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[20]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[21]  B. Giasson,et al.  Chaperone‐like activity of synucleins , 2000, FEBS letters.

[22]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[23]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[24]  M. Moskowitz,et al.  Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. , 1994, Science.

[25]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[26]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[27]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[28]  R. Nussbaum,et al.  α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases* , 2001, The Journal of Biological Chemistry.

[29]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[30]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[31]  W. Honer,et al.  Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. , 1998, The American journal of pathology.

[32]  Robert H. Brown,et al.  Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.

[33]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[34]  H. Ischiropoulos Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.

[35]  A. Morris,et al.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.

[36]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  S. Przedborski,et al.  Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[39]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[41]  S. Shin,et al.  Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.

[42]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[43]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[44]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[45]  A. Favier,et al.  A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis , 2001 .

[46]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[47]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[48]  S. Snyder,et al.  Neuronal Nitric Oxide Synthase Activation and Peroxynitrite Formation in Ischemic Stroke Linked to Neural Damage , 1999, The Journal of Neuroscience.

[49]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[50]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.